International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 3 , Pages 574-580 , 1 July 2002

The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer

Presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology, San Francisco, CA, November, 2001.

  • Mark A Ritter, M.D., Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests and correspondence to: Mark A. Ritter, M.D., Ph.D., Department of Human Oncology, K4/B100, 600 Highland Ave., Madison, WI 53792 USA. Tel: (608) 263-8509; Fax: (608) 263-9167
    • Department of Human Oncology, University of Wisconsin, Madison, WI USA
    • ,
  • Kennedy W Gilchrist, M.D.

      Affiliations

    • Department of Pathology, University of Wisconsin, Madison, WI USA
    • ,
  • Marta Voytovich, M.D.

      Affiliations

    • Department of Pathology, University of Wisconsin, Madison, WI USA
    • ,
  • Richard J Chappell, Ph.D.

      Affiliations

    • Department of Biostatistics, University of Wisconsin, Madison, WI, USA
    • ,
  • Bret M Verhoven

      Affiliations

    • Department of Human Oncology, University of Wisconsin, Madison, WI USA

Received 11 December 2001 ,Accepted 28 January 2002.

References 

  1. Kuban DA, el-Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 1992;24(3):409–414
  2. Pilepich MV, Krall JM, al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma (A randomized comparative trial of the Radiation Therapy Oncology Group). Urology. 1995;45(4):616–623
  3. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295–300
  4. Hanks GE, Lee WR, Hanlon AL, et al.  Conformal technique dose escalation for prostate cancer (Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML). Int J Radiat Oncol Biol Phys. 1996;35(5):861–868
  5. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;39(5):1011–1018
  6. Zelefsky MJ, Leibel SA, Gaudin PB, et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. [see comments] Int J Radiat Oncol Biol Phys. 1998;41(3):491–500
  7. Roach M, Meehan S, Kroll S, et al.  Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. [see comments] J Urol. 1996;156(5):1719–1723
  8. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):553–561
  9. Pollack A, Zagars GK, Smith IG, Antolak JA, Rosen II. Preliminary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45(Suppl. 3):146a–147a
  10. Partin AW, Kattan MW, Subong EN, et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445–1451
  11. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity (Implications for radiotherapy). Radiother Oncol. 1996;40(3):197–223
  12. Scherr DS, Vaughan ED, Wei J, et al.  BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999;162(1):12–16
  13. Cheng L, Sebo TJ, Cheville JC, et al.  p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999;85(6):1293–1299
  14. Grossfeld GD, Olumi AF, Connolly JA, et al.  Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998;159(5):1437–1443
  15. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998;52(6):1085–1090
  16. Grignon DJ, Caplan R, Sarkar FH, et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma (A study based on RTOG 8610). J Natl Cancer Inst. 1997;89(2):158–165
  17. Rovinski B, Benchimol S. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene. 1988;2(5):445–452
  18. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol. 1996;27(6):573–580
  19. ASTRO . Panel Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  20. Chiarugi V, Magnelli L, Cinelli M. Role of p53 mutations in the radiosensitivity status of tumor cells. Tumori. 1998;84(5):517–520
  21. Meyn MS. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res. 1995;55(24):5991–6001
  22. Meyn RE, Stephens LC, Mason KA, Medina D. Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo (Significance of gland differentiation and p53 status). Int J Cancer. 1996;65(4):466–472
  23. Sakakura C, Sweeney EA, Shirahama T, et al.  Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer. 1996;67(1):101–105
  24. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(8):1935–1940
  25. Nogueira CP, Dolan RW, Gooey J, et al.  Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope. 1998;108(3):345–350
  26. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck (A clinicopathologic and immunohistochemical study). J Clin Oncol. 1997;15(3):1030–1038
  27. Servomaa K, Kiuru A, Grenman R, Pekkola-Heino K, Pulkkinen JO, Rytomaa T. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif. 1996;29(5):219–230
  28. Sheridan MT, O’Dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5(4):180–186
  29. Biard DS, Martin M, Rhun YL, et al.  Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res. 1994;54(13):3361–3364
  30. Sirzen F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R. Spontaneous and radiation-induced apoptosis in lung carcinoma cells with different intrinsic radiosensitivities. Anticancer Res. 1998;18(2A):695–699
  31. Colletier PJ, Ashoori F, Cowen D, et al.  Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys. 2000;48(5):1507–1512
  32. Cowen D, Salem N, Ashoori F, et al.  Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin Cancer Res. 2000;6(11):4402–4408
  33. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology. 1998;51(2):346–351
  34. Bylund A, Stattin P, Widmark A, Bergh A. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol. 1998;49(2):143–148
  35. Dulic V, Kaufmann WK, Wilson SJ, et al.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76(6):1013–1023
  36. Smith ML, Chen IT, Zhan Q, et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 1994;266(5189):1376–1380
  37. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293–299
  38. Siles E, Villalobos M, Valenzuela MT, et al.  Relationship between p53 status and radiosensitivity in human tumour cell lines. Br J Cancer. 1996;73(5):581–588
  39. Li CY, Nagasawa H, Dahlberg WK, Little JB. Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. Oncogene. 1995;11(9):1885–1892
  40. Langendijk JA, Thunnissen FB, Lamers RJ, de Jong JM, ten Velde GP, Wouters EF. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol. 1995;36(3):218–224
  41. Bourhis J, Bosq J, Wilson GD, et al.  Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. Int J Cancer. 1994;57(4):458–462

PII: S0360-3016(02)02781-5

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 3 , Pages 574-580 , 1 July 2002

Article Tools

* Image Usage & Resolution